Trial Profile
Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-Moderate Alzheimer's Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Intepirdine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 20 Jul 2017 Results of an analysis examining the difference in the magnitude of decline in cognition over 48 weeks between intepirdine in conjunction with donepezil and donepezil alone, reported on a numeric and percentage basis.presented at the Alzheimer's Association International Conference 2017
- 20 Jul 2017 Results of responder analysis presented at the Alzheimer's Association International Conference 2017
- 20 Jul 2017 Results of medicare cost benefit of intepirdine from this study presented at the Alzheimer's Association International Conference 2017